Skip Navigation


Carcinogenesis Advance Access originally published online on August 11, 2007
Carcinogenesis 2007 28(9):1851-1858; doi:10.1093/carcin/bgm176
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/9/1851    most recent
bgm176v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lea, I.A.
Right arrow Articles by Dunnick, J.K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lea, I.A.
Right arrow Articles by Dunnick, J.K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns

I.A. Lea, M.A. Jackson, X. Li, S. Bailey, S.D. Peddada1 and J.K. Dunnick1,*

Integrated Laboratory Systems, Inc., Research Triangle Park, NC 27709, USA
1 National Institutes of Environmental Health Sciences, Research Triangle Park, NC 27709, USA

* To whom correspondence should be addressed. Tel: +1 919 541 4811; Fax: +1 919 541 4255; Email: dunnickj{at}niehs.nih.gov

Correspondence may also be addressed to I.A. Lea. Tel: +1 919 544 4589; Fax: +1 919 544 0380; Email: ilea{at}ils-inc.com

Cancer is a complex disease that involves the accumulation of both genetic and epigenetic alterations of numerous genes. Data in the Genetic Alterations in Cancer database for gene mutations and allelic loss [loss of heterozygosity (LOH)] in human tumors (e.g. lung, oral, esophagus, stomach and colon/rectum) were reviewed. Results for the genes and pathways implicated in tumor development at these sites are presented. Mutation incidence, spectra and codon specificity are described for lung, larynx and oral tumors. LOH occurred more frequently than gene mutations in tumors from all sites examined. The cell cycle gene, TP53 (all sites), and cell signaling gene, APC (colorectal and gastric cancers), were the only genes with similar incidences of LOH and mutation. Alterations of one or more cell cycle and cell signaling genes were reported for tumors from each site. Site-specific activation was apparent in the cell signaling mitogen-activated protein kinase oncogenes (KRAS in lung, HRAS in oral cancers and BRAF in esophageal and colorectal cancers). Analysis of genetic changes in lung tumors showed that the incidence of mutations in the TP53 and KRAS genes and the incidence of LOH in the FHIT gene were significantly greater in smokers versus non-smokers (P < 0.01). In lung and oral cancers, the TP53 GC -> TA transversion frequency increased with tobacco smoke exposure (P < 0.05). Furthermore, the TP53 mutational hot spots for lung and laryngeal cancers from smokers included codons 157, 245 and 273, whereas for oral tumors included codons 280 and 281.

Abbreviations: GAC, Genetic Alterations in Cancer; LOH, loss of heterozygosity; MAPK, mitogen-activated protein kinase

Received May 16, 2007; revised July 16, 2007; accepted July 20, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.